Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Occupational HIV Transmission Among Male Adult Film Performers - Multiple States, 2014.

Wilken JA, Ried C, Rickett P, Arno JN, Mendez Y, Harrison RJ, Wohlfeiler D, Bauer HM, Joyce MP, Switzer WM, Heneine W, Shankar A, Mark KE.

MMWR Morb Mortal Wkly Rep. 2016 Feb 12;65(5):110-4. doi: 10.15585/mmwr.mm6505a3.


Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences.

Mark KE, Spruance S, Kinghorn GR, Sacks SL, Slade HB, Meng TC, Selke S, Magaret A, Wald A.

Antimicrob Agents Chemother. 2014 Sep;58(9):5016-23. doi: 10.1128/AAC.00077-14.


Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.


Estimated HIV Incidence in California, 2006-2009.

Scheer S, Nakelsky S, Bingham T, Damesyn M, Sun D, Chin CS, Buckman A, Mark KE.

PLoS One. 2013;8(2):e55002. doi: 10.1371/journal.pone.0055002.


Regional differences among HIV patients in care: California medical monitoring project sites, 2007-2008.

Scheer S, Hughes AJ, Tejero J, Damesyn MA, Mark KE, Arguello TM, Wohl AR.

Open AIDS J. 2012;6:188-95. doi: 10.2174/1874613601206010188.


Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.

Moss NJ, Magaret A, Laing KJ, Kask AS, Wang M, Mark KE, Schiffer JT, Wald A, Koelle DM.

J Virol. 2012 Sep;86(18):9952-63. doi: 10.1128/JVI.00829-12.


Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team..

J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342.


Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).

Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, Corey L; NIAID HIV Vaccine Trials Network..

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):238-44. doi: 10.1097/QAI.0b013e31821acb5.


Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107.


Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults.

Mark KE, Wald A, Magaret AS, Selke S, Kuntz S, Huang ML, Corey L.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):482-8. doi: 10.1097/QAI.0b013e3181d91322.


Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, Wald A, Corey L.

Sci Transl Med. 2009 Nov 18;1(7):7ra16. doi: 10.1126/scitranslmed.3000193.


Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L.

J Infect Dis. 2008 Oct 15;198(8):1141-9. doi: 10.1086/591913.


Internet and email use among STD clinic patients.

Mark KE, Wald A, Drolette L, Golden MR.

Sex Transm Dis. 2008 Nov;35(11):960-5. doi: 10.1097/OLQ.0b013e3181824f4d.


Contraception among HIV concordant and discordant couples in Zambia: a randomized controlled trial.

Mark KE, Meinzen-Derr J, Stephenson R, Haworth A, Ahmed Y, Duncan D, Westfall A, Allen S.

J Womens Health (Larchmt). 2007 Oct;16(8):1200-10.


Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.

Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, Leone P, Bergland VA, Wald A.

J Infect Dis. 2007 May 1;195(9):1324-31.


Targeted prenatal herpes simplex virus testing: can we identify women at risk of transmission to the neonate?

Mark KE, Kim HN, Wald A, Gardella C, Reed SD.

Am J Obstet Gynecol. 2006 Feb;194(2):408-14.


Risk factors for infection during a dengue-1 outbreak in Maui, Hawaii, 2001.

Hayes JM, Rigau-PĂ©rez JG, Reiter P, Effler PV, Pang L, Vorndam V, Hinten SR, Mark KE, Myers MF, Street K, Bergau L, Meyer C, Amador M, Napier M, Clark GG, Biggerstaff BJ, Gubler DJ.

Trans R Soc Trop Med Hyg. 2006 Jun;100(6):559-66.


Prevalence of and associated risk factors for fluoroquinolone-resistant Neisseria gonorrhoeae in California, 2000-2003.

Bauer HM, Mark KE, Samuel M, Wang SA, Weismuller P, Moore D, Gunn RA, Peter C, Vannier A, DeAugustine N, Klausner JD, Knapp JS, Bolan G.

Clin Infect Dis. 2005 Sep 15;41(6):795-803.

Items per page

Supplemental Content

Loading ...
Support Center